Pharmaceutical Commerce: Addressing Rx Affordability

Although historic and important Medicare reforms were included in the Inflation Reduction Act, many patients enrolled in Medicare Part D will continue to face challenges affording their out-of-pocket prescription medications even once all the reforms are implemented. And many will continue to turn to charitable patient assistance foundations, like PAN, for support.

In this column for Pharmaceutical Commerce, PAN’s President and CEO, Kevin L. Hagan, and Chief Advocacy and Engagement Officer, Amy Niles, share more about why the $2,000 annual out-of-pocket cap in 2025 won’t completely address patients’ need for financial assistance.